The History of Target-Controlled Infusion
About this course
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
The International Anesthesia Research Society designates each Journal-Based CME activity (article) for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The IARS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Anesthesia & Analgesia, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
The International Anesthesia Research Society designates each CME activity for a maximum of 1 hour of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The International Anesthesia Research Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Jeffrey B. Gross, M.D., Editor, Anesthesia & Analgesia CME Program and Steven L. Shafer, M.D., Editor-in-Chief of Anesthesia & Analgesia, report that they have no financial relationships or interests to disclose relative to the content of the CME program. The links attached to each name will direct you to the disclosure statements by Drs. Gross and Shafer.
This CME program is supported entirely by the International Anesthesia Research Society. There is no commercial sponsorship of this program.
Upon completing this course, anesthesiologists will be better prepared to manage their patients using target-controlled infusion systems.
Jeffrey B. Gross, M.D. (CME Editor): No conflicts
Authors of the cited article have indicated the following potential conflicts of interest:
Michel MRF Struys is co-owner of RUGLOOP, a software program for target-controlled infusion. His department has received non-educational grants and fees for consultancy and advice in the field of medical device technology from Dräger Medical (Lübeck, Germany), Fresenius Kabi (Germany), Baxter (Chicago, USA), Sphere Medical (UK). He is an editor to the British Journal of Anaesthesia.
Tom De Smet is co-owner of RUGLOOP, a software program for target-controlled infusion, and owns the medical engineering company Demed, Temse, Belgium. He has received fees for consultancy from Carefusion and Fresenius Kabi.
Iain Glen is a former employee of ICI, ZENECA, ASTRAZENECA (retired 2000) and was closely involved in the clinical validation and commercial development of the Diprifusor™ TCI system. He was owner and a director of Glen Pharma Ltd, which traded as a Consultancy between 2000 and 2010, and worked with AstraZeneca, GlaxoSmithKline, NeuroSearch, Labopharm, Claris Life Sciences, Carefusion and Fresenius Kabi. Since 2010, he has been paid by Anaesthesia Technology Limited for documentation relating to Diprifusor™ development.
Hugo E.M. Vereecke: The research group has received unrestricted research grants from Dräger Medical (Lübeck, Germany), Carefusion Inc (UK), Fresenius Kabi (Germany), Sphere Medical (UK).
The department where Anthony R Absalom works has received unrestricted research grants from Dräger Medical (Lübeck, Germany) and CarefusionInc (UK). He is a paid consultant for Janssen (Belgium), and an editor of the British Journal of Anaesthesia.
Thomas W. Schnider is a paid consultant for Codan Medical (Switzerland).